Related Experiment Video

Updated: Jun 23, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Total and high molecular weight adiponectin in patients with coronary artery disease

Ayman El-Menyar1, Nasser Rizk, Abdulrahman D Al Nabti

  • 1Department of Cardiology and Cardiovascular Surgery, Qatar.

Journal of Cardiovascular Medicine (Hagerstown, Md.)
|May 12, 2009
PubMed

Insights

High molecular weight adiponectin (HMW) may be a superior biomarker for coronary artery disease (CAD) compared to total adiponectin. Lower HMW adiponectin levels in diabetics may explain their poorer CAD outcomes.

Area of Science:

  • Cardiovascular Research
  • Metabolic Syndrome Studies
  • Biomarker Discovery

Background:

  • Serum adiponectin levels are inversely associated with coronary artery disease (CAD) severity.
  • Understanding specific adiponectin isoforms, like high molecular weight adiponectin (HMW), is crucial for refining cardiovascular risk assessment.

Purpose of the Study:

  • To evaluate the clinical significance of measuring both total and HMW adiponectin.
  • To compare adiponectin levels in peripheral veins versus coronary artery ostia in CAD patients.

Main Methods:

  • Simultaneous measurement of total and HMW adiponectin in coronary ostia and peripheral veins.
  • Inclusion of 134 patients: 57 with acute coronary syndrome (ACS), 44 with stable angina, and 33 healthy controls.
  • Analysis of venous lipid profiles, inflammatory markers (CRP, TNF-α, IL-6), and insulin levels.

Main Results:

  • HMW adiponectin in coronary ostia correlated with venous total and HMW adiponectin levels.
  • CAD patients exhibited lower mean total and HMW adiponectin levels compared to controls.
  • Ostial HMW adiponectin was higher in ACS patients than stable angina patients.
  • Diabetic CAD patients had significantly lower ostial total and HMW adiponectin levels than non-diabetic CAD patients.

Conclusions:

  • HMW adiponectin and its ratio to total adiponectin may serve as improved biomarkers for CAD.
  • Ostial adiponectin levels in ACS could reflect redistribution to acute lesions.
  • Diminished HMW adiponectin in diabetes mellitus may contribute to worse CAD outcomes in this population.
Abstract

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...